White House's TrumpRx names Novartis among drugmakers offering steep prescription discounts
- White House names Novartis among companies joining TrumpRx to offer steep prescription discounts and direct sales.
- TrumpRx targets chronic therapies where Novartis has major market share (diabetes, asthma, HIV, hepatitis C, MS, cardiovascular).
- Participation poses Novartis commercial, reputational, supply, and pharmacy-partnership challenges despite potential patient cost reductions.
Novartis among drugmakers tied to White House TrumpRx rollout
Novartis is named by the White House as one of several major pharmaceutical companies committing to participate in a new federal initiative, TrumpRx, aimed at lowering prescription drug costs by offering steep discounts and, in some cases, selling medicines directly to consumers. The administration presents the programme as targeting costly chronic therapies for conditions such as diabetes, asthma, HIV, hepatitis C, multiple sclerosis and cardiovascular disease — areas in which Novartis and its peers hold significant market share. Officials say agreements with drugmakers are expected to expand access and save Americans billions, a claim that frames the initiative as a high-profile shift in how manufacturers approach pricing and distribution.
The Trump administration is positioning the initiative as a market-oriented response to drug affordability, and Novartis faces immediate commercial and reputational considerations as a participant. Direct-to-consumer sales and steep list-price reductions could alter established distribution and rebate arrangements, forcing companies to reconcile short-term discounting with longer-term pricing strategies and negotiated payer contracts. For Novartis, which sells treatments across the chronic-disease spectrum, the initiative creates both an opportunity to be seen as reducing patient out-of-pocket costs and a challenge in managing supply, channel incentives and existing pharmacy partnerships.
Industry executives and policy analysts say the programme could set a precedent for future government-led pricing agreements, influencing how multinational firms like Novartis negotiate with payers and design access programmes. But practical implementation questions — which pharmacies will participate, how formularies are set and which patients qualify — remain unresolved, leaving companies to weigh potential compliance, logistics and legal implications while responding to public and political scrutiny.
Partner companies, price examples and backers
The White House lists nine major companies as having reached deals and media report at least 16 manufacturers negotiating participation; alongside Novartis, names include Amgen, Merck, Sanofi and Bristol Myers Squibb. The administration highlights examples such as Merck cutting the price of Januvia and Bristol Myers Squibb steeply discounting an HIV therapy. GoodRx and other industry figures publicly welcome moves that align with broader efforts to reduce drug prices.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

